VIEWS: 4 PAGES: 1 POSTED ON: 8/16/2012
Comprehensive Review Saturday, February 28, 2009, Atlanta, GA of Lung Cancer Buckhead Hotel Atlanta 3405 Lenox Road NE, Atlanta, GA 30326 Statement of Need/Program Overview Telephone: (404) 261-9250 This program is intended to facilitate interaction among oncologists and nurses interested in development of novel therapeutics for treatment of lung Program Director cancer. In addition to multimodality therapy, adjuvant therapy, this sympo- sium will present data of most promising emerging agents currently in devel- Chandra P. Belani, MD opment for the treatment of lung cancer. There will be in-depth discussion Miriam Beckner Distinguished Professor of Medicine Penn State of both antiangiogenic agents and inhibitors of EGFR pathways. Drugs that Milton S. Hershey Medical Center target multiple signaling pathways will also be given signiﬁcant focus. Penn State College of Medicine Physician Continuing Medical Education Deputy Director, Penn State Cancer Institute, Hershey, PA Accreditation Statement: This activity has been planned and implemented in ac- cordance with the Essential Areas and policies of the Accreditation Council for Con- Agenda Topics tinuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Novel Agents in Combination with Radiation Therapy for Lung Cancer Institute for Medicine (PIM) and International Cancer Network. PIM is accredited by Management of Stage III Disease: Multimodality Therapy for Lung Cancer the ACCME to provide continuing medical education for physicians. Small Cell Lung Cancer: Novel Agents and Recent Advances Credit Designation: Postgraduate Institute for Medicine designates this educational activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)TM. Physicians should Targeting VEGF and EGFR in Lung Cancer only claim credit commensurate with the extent of their participation in the activity. Bevacizumab: Implications of Recent data in Non–Small-Cell Lung Cancer Nursing Continuing Education Small Molecule VEGF Receptor Tyrosine Kinase Inhibitors and Multikinase Purpose: The purpose of this educational meeting is to assist healthcare providers Inhibitors in the Treatment of Lung Cancer develop appropriate treatment strategies that minimize side effects and optimize Targeting EGFR-Monoclonal Antibodies and EGFR Tyrosine Kinase outcomes in patients with lung cancer. Inhibitors in Lung Cancer Accreditation Statements: CNA/ANCC This educational activity for 5.5 contact hours is provided by Postgraduate Institute State of the Art and Other Targeted Agents in Non–Small-Cell Lung Cancer for Medicine (PIM). First-Line Chemotherapy Options for Advanced Lung Cancer PIM is an approved provider of continuing nursing education by the Colorado Second-line Chemotherapeutic Options for Lung Cancer Nurses Association, an accredited approver by the American Nurses Credentialing Novel Agents in Lung Cancer: HDAC Inhibitors, Nab-Paclitaxel, Center’s Commission on Accreditation. Bortezomib, and Others Pharmacist Continuing Education Accreditation Statement: Postgraduate Institute for Medicine is accredited by the Accredi- tation Council for Pharmacy Education as a provider of continuing pharmacy education. Target Audience Medical Oncologists, Radiation Oncologists, Nurses, Pharmacists, Credit Designation: Postgraduate Institute for Medicine designates each session of Physician Assistants, Fellows in training this continuing education activity for 1.8 contact hour(s) (0.18 CEUs) of the Ac- creditation Council for Pharmacy Education. (Session I Universal Program Number Jointly sponsored by International Cancer Network and Postgraduate Institute for 809-999-09-001-L01-P; Session II Universal Program Number 809-999-09-002- Medicine L01-P; Session III Universal Program Number 809-999-09-003-L01-P). Saturday, February 28, 2009 - Atlanta, GA First Name_______________________________ Middle Initial______ Last Name_______________________________________________ ❑ Physician ❑ Pa-C ❑ Fellow ❑ NP ❑ PhD ❑ Pharmacist ❑ Industry ❑ Nurse ❑ Other Speciality__________________________________________________________________________________________________________ Mailing Address_____________________________________________________________________________________________________ City_______________________________________________ State___________________ Zip Code________________________________ Phone__________________________ Fax________________________ E-Mail_________________________________________________ Registration Fee Fax registration to: Registration fee partially covers continental breakfast, lunch and syllabus book 443-267-0016 ❑ Physicians $50.00 ❑ Nurses, Pharmacists, others $30.00 ❑ Fellows No Registration Fee ❑ *Industry $325.00 Mail registration to: PO Box 116609 *Person(s) employed by for-proﬁt organizations such as pharmaceutical and biotech companies, and ﬁnancial institutions Carrollton, TX 75011-6609 Payment may be made: ❑ MC ❑ Visa ❑ Discover ❑ Amex ❑ Check Credit Card Number___________________________ Expiration Date_______________ Security code (AmEx on front)_________________ Name and address as it appears on Credit Card_____________________________________________________________________________ __________________________________________________________________________________________________________________ Signature___________________________________________________________________________________________________________ Register online at www.Internationalcancernetwork.com Please make checks payable to International Cancer Network. Mail checks to PO Box 116609, Carrollton, TX 75011-6609 To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. If you have any questions please call 972-939-6206 or E-mail: firstname.lastname@example.org If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.
Pages to are hidden for
"Comprehensive Review of Lung Cancer "Please download to view full document